• WKN: 593700
  • ISIN: DE0005937007
  • Land: Deutschland

Nachricht vom 26.01.2021 | 13:51

MAN SE: Executive Board members of MAN SE and MAN Truck & Bus SE and employee representatives sign key points of comprehensive realignment

MAN SE / Key word(s): Restructure of Company
MAN SE: Executive Board members of MAN SE and MAN Truck & Bus SE and employee representatives sign key points of comprehensive realignment

26-Jan-2021 / 13:51 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Munich, January 26, 2021 - The Executive Board members of MAN SE and MAN Truck & Bus SE and the employee representatives have signed an agreement on the key points of a comprehensive realignment of MAN Truck & Bus SE. This agreement serves as the basis for drafting collective bargaining and works agreements, which are to be concluded this year.

The concept presented by the Executive Boards of MAN SE and MAN Truck & Bus SE on September 11, 2020, formed the starting point of the negotiations.

The agreement that has been reached sets out a restructuring of all areas of the MAN Truck & Bus business. The agreement on the key points supports a package of measures with the aim of improving operating result by up to €1.7 billion. The Executive Board sees the agreement as a positive since it makes a substantial contribution to achieving a significant and sustained improvement in operating result. The Executive Board confirms the overarching strategic goal of achieving an operating return on sales (RoS) of 8% over the cycle.

Among other things, the key point paper agreed also sets out a repositioning of the development and production network with a strong focus on future technologies. The Wittlich site will be downsized but maintained. The Plauen site as well as the Steyr site in Austria, which has around 2,200 employees, are being discussed. The Executive Board is reviewing all options in this respect, including the possibility of selling or relinquishing the sites.

The measures planned also entail cutting around 3,500 jobs across all areas of the company in Germany by the end of 2022. The job cuts are to be implemented in the most socially responsible manner possible.

In total, the restructuring measures, including the measures in connection with the Plauen and the Steyr site, which are still to be defined, are currently expected to cost in the high triple-digit millions for the entire restructuring period. The majority of the expenses will be for personnel measures.


Dr. Martin Gstaltmeyr
General Counsel
T +49 175 579 2043

Dachauer Str. 641
80995 Munich, Germany

26-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie


Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021